Non-invasive plasma treatment for HPV infections
Treatment of Infections of the Cervix Uteri With High- and Low-risk Variants of the Human Papillomavirus Using Non-invasive Physical Plasma
University Hospital Tuebingen · NCT06291311
This study is testing a new non-invasive plasma treatment to see if it can help people clear HPV infections without causing any cervical issues.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 50 (estimated) |
| Ages | 18 Years and up |
| Sex | Female |
| Sponsor | University Hospital Tuebingen (other) |
| Locations | 1 site (Tübingen) |
| Trial ID | NCT06291311 on ClinicalTrials.gov |
What this trial studies
This observational clinical trial aims to evaluate the effectiveness of non-invasive physical plasma (NIPP) in eradicating HPV infections in patients without cervical dysplasia. Conducted at the University Hospital Tübingen, the study will involve obtaining tissue samples at defined intervals through minibiopsy to analyze the cellular, molecular, and immunological effects of the treatment. The trial will compare outcomes between patients receiving NIPP and a control group, utilizing various molecular biological, histological, and microscopic methods for analysis.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older with confirmed HPV infections and visible transformation zones on the cervix.
Not a fit: Patients with invasive disease or those with serious cardiovascular conditions may not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could provide a non-invasive option for eradicating HPV infections, potentially reducing the risk of cervical cancer.
How similar studies have performed: While there is ongoing research into non-invasive treatments for HPV, this specific approach using NIPP is novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Inclusion criteria for NIPP treatment * Age ≥ 18 years * mRNA or DNA-based virus detection by smear (also external findings) * Clearly visible transformation zone of the cervix and margins of the lesions corresponding to T1/T2 * Written informed consent to participate in the study * Inclusion criteria for control group * Age ≥ 18 years * Swab-based mRNA or DNA-based virus detection (also external findings) * Clearly visible transformation zone of the cervix corresponding to T1/T2 * Written informed consent to participate in the study Exclusion criteria: The following exclusion criteria apply to both groups of patients (NIPP treatment and control group). * Transformation zone not fully visible * Evidence of invasive disease * Serious cardiovascular diseases
Where this trial is running
Tübingen
- University Hospital Tuebingen, Department of Women's Health — Tübingen, Germany (RECRUITING)
Study contacts
- Principal investigator: Martin Weiss, Dr. med. — University Hospital Tuebingen
- Study coordinator: Martin Weiss, Dr. med.
- Email: martin.weiss@med.uni-tuebingen.de
- Phone: +497071 29 82211
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: HPV Infection, Cervical Cancer